Then you put pat sm6 and carfilzomib together for improved performance and you can improve on this result
The multiple myeloma drug Kyprolis (carfilzomib), acquired through the $10.4 billion Onyx buy, grew 6% from the second quarter to $65 million
http://www.pharmatimes.com/Article/13-10-23/Strong_quarter_for_Amgen_helped_by_denosumab_drugs.aspx
how low tomorrow, page-11
-
- There are more pages in this discussion • 9 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
0.7¢ |
Change
0.000(0.00%) |
Mkt cap ! $14.40M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 15 | 5382389 | 0.6¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 0.7¢ | 2352699 | 1 |
View Market Depth
| Last trade - 16.12pm 02/08/2024 (20 minute delay) ? |
| PAB (ASX) Chart |
Day chart unavailable